Stoke Therapeutics shareholders approve routine annual meeting matters, 27% oppose exec pay

Filed June 4, 2026 · Period ending June 3, 2026 · ~1 min read

Key Changes

• medium

  Shareholders approved executive compensation on advisory vote with 73% support, but 27% voted against, suggesting notable concern about pay levels or structure disclosed in April proxy.

  Item 5.07 verify on EDGAR →
• low

  Three Class I directors elected to three-year terms through 2029: G. Clare Kahn, Adrian Krainer, and Julie Anne Smith, with varying vote margins.

  Item 5.07 verify on EDGAR →
• low

  Ernst & Young ratified as independent auditor for fiscal 2026 with over 99% approval, continuing existing audit relationship.

  Item 5.07 verify on EDGAR →